UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000003737 |
|---|---|
| Receipt number | R000004512 |
| Scientific Title | Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910) |
| Date of disclosure of the study information | 2010/06/11 |
| Last modified on | 2019/03/31 05:48:48 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2010/06/11 14:07:54 | ||
| 2 | Update | 2011/06/13 12:24:29 | Name of person sending information Organization Division name Address |
|
| 3 | Update | 2011/12/16 11:10:48 | Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
| 4 | Update | 2013/12/16 21:01:17 | TEL Address Address TEL |
|
| 5 | Update | 2014/05/01 15:56:15 | Recruitment status |
|
| 6 | Update | 2016/06/13 17:41:46 | Name of primary person or sponsor Organization Organization Organization Category of Funding Organization |
|
| 7 | Update | 2018/06/29 18:51:40 | Email1 |
|
| 8 | Update | 2019/03/31 05:48:48 | Recruitment status Date of IRB Last follow-up date |
